Characterization of Pupylation in Mycobacterium tuberculosis
结核分枝杆菌化脓的特征
基本信息
- 批准号:8389647
- 负责人:
- 金额:$ 35.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-12-01 至 2015-11-30
- 项目状态:已结题
- 来源:
- 关键词:AntibioticsAntitubercular AgentsBacteriaBiochemicalBiochemistryBiologicalBiologyCause of DeathComplexCoupledDataDevelopmentDrug resistanceEnzymatic BiochemistryEnzymesEukaryotaExtreme drug resistant tuberculosisFoundationsFutureGeneticGenus MycobacteriumGlutamatesGlutamineGoalsGrowthIn VitroLigaseLigationLysineMediatingModelingMolecularMolecular ChaperonesMusMycobacterium tuberculosisNitric OxidePathogenesisPathway interactionsPost-Translational Protein ProcessingProcessProductionProkaryotic CellsProteinsResistanceShapesSpecificityStructureSystemTechniquesToxic effectTuberculosisUbiquitinUbiquitin Like ProteinsVirulencebasedeamidationdrug developmentfactor Ainterestkillingsmacrophagemulticatalytic endopeptidase complexmutantmycobacterialnovelprotein degradationpublic health relevancepuptuberculosis drugstuberculosis treatmentubiquitin ligase
项目摘要
DESCRIPTION (provided by applicant): Tuberculosis kills about 2 million people globally every year. A key defense against Mycobacterium tuberculosis (Mtb) infections is the production of nitric oxide (NO) by macrophages. Although NO controls Mtb growth, it rarely sterilizes the bacterium from the host, suggesting Mtb has mechanisms to resist NO toxicity. The Mtb proteasome is one such mechanism that is required for resistance to NO as well as causing death in mice. Thus, we are interested in targeting the proteasome and its associated factors for drug development. The proteasome is a multi-subunit, barrel shaped complex that degrades proteins. We found that the proteins Mpa and PafA are required for protein degradation: Mpa is thought to chaperone proteins into the proteasome core and PafA appears to be required for the attachment of a prokaryotic ubiquitin-like protein (Pup) onto substrates targeted for destruction. Pup represents the first known post-translational small protein modifier identified in any prokaryote. Little is known about how Pup is conjugated to its target substrates thus we propose to identify and characterize all proteins required for "pupylation" using genetic, biochemical and molecular biological techniques. In addition, we have recently discovered pupylation is reversible, thus we are in the process of characterizing the "depupylation" pathway. The elucidation of the Pup-proteasome sytem of Mtb will hopefully lay the foundation for the discovery and characterization of other posttranslational modification systems in all bacteria. Furthermore, these enzymes may represent new targets for the development of anti- tuberculosis drugs.
描述(由申请人提供):每年全球约有200万人杀死约200万人。针对结核分枝杆菌(MTB)感染的关键防御是巨噬细胞生产一氧化氮(NO)。尽管没有对照MTB的生长,但它很少对宿主的细菌进行消毒,这表明MTB具有抵抗毒性的机制。 MTB蛋白酶体是一种这样的机制,它是对NO耐药性以及在小鼠中导致死亡所必需的一种机制。因此,我们有兴趣针对蛋白酶体及其与药物开发相关的因素。蛋白酶体是一种多纯料的桶形复合物,可降解蛋白质。我们发现,蛋白质MPA和PAFA是蛋白质降解所必需的:MPA被认为是将蛋白质蛋白蛋白与蛋白酶体核心中的伴侣蛋白,而PAFA似乎是将原核生物泛素样蛋白(PUP)连接到靶标而靶向破坏的蛋白质样蛋白(PUP)所必需的。 PUP代表了在任何原核生物中鉴定出的第一个已知的翻译后小蛋白质修饰剂。关于如何将幼崽偶联到其靶标底物,因此我们建议使用遗传,生化和分子生物学技术来识别和表征“硫化型”所需的所有蛋白质。此外,我们最近发现硫匹贝化是可逆的,因此我们正在表征“甲基化”途径。 MTB的幼崽 - 凝血体系统的阐明将为所有细菌中其他翻译后修饰系统的发现和表征奠定基础。此外,这些酶可能代表开发抗结核药物的新靶标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Katerina Heran Darwin其他文献
Katerina Heran Darwin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Katerina Heran Darwin', 18)}}的其他基金
2022 Microbial Toxins and Pathogenicity Gordon Research Conference and Seminar
2022年微生物毒素与致病性戈登研究会议暨研讨会
- 批准号:
10314283 - 财政年份:2021
- 资助金额:
$ 35.74万 - 项目类别:
METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS
代谢醛作为抗结核病的免疫效应物
- 批准号:
10028048 - 财政年份:2020
- 资助金额:
$ 35.74万 - 项目类别:
METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS
代谢醛作为抗结核病的免疫效应物
- 批准号:
10410493 - 财政年份:2020
- 资助金额:
$ 35.74万 - 项目类别:
METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS
代谢醛作为抗结核病的免疫效应物
- 批准号:
10172843 - 财政年份:2020
- 资助金额:
$ 35.74万 - 项目类别:
METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS
代谢醛作为抗结核病的免疫效应物
- 批准号:
10633100 - 财政年份:2020
- 资助金额:
$ 35.74万 - 项目类别:
PROTEASOME-DEPENDENT DEGRADATION IN MYCOBACTERIUM TUBERCULOSIS
结核分枝杆菌中蛋白酶体依赖性降解
- 批准号:
9102361 - 财政年份:2010
- 资助金额:
$ 35.74万 - 项目类别:
PROTEASOMAL REGULATION AND PROTEIN QUALITY CONTROL IN M. TUBERCULOSIS
结核分枝杆菌中的蛋白酶体调节和蛋白质质量控制
- 批准号:
10590761 - 财政年份:2010
- 资助金额:
$ 35.74万 - 项目类别:
Characterization of Pupylation in Mycobacterium tuberculosis
结核分枝杆菌化脓的特征
- 批准号:
8619579 - 财政年份:2010
- 资助金额:
$ 35.74万 - 项目类别:
PROTEASOMAL REGULATION AND PROTEIN QUALITY CONTROL IN M. TUBERCULOSIS
结核分枝杆菌中的蛋白酶体调节和蛋白质质量控制
- 批准号:
10383709 - 财政年份:2010
- 资助金额:
$ 35.74万 - 项目类别:
Characterization of Pupylation in Mycobacterium tuberculosis
结核分枝杆菌化脓的特征
- 批准号:
8197553 - 财政年份:2010
- 资助金额:
$ 35.74万 - 项目类别:
相似国自然基金
L12与L10蛋白相互作用作为新型抗结核药物分子靶标的研究及其阻断剂的筛选
- 批准号:81001461
- 批准年份:2010
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
抗结核特异抗体靶向造影剂对免疫缺陷性结核病诊断的动物实验研究
- 批准号:81071153
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis
噻唑啉-吡啶酮化合物作为结核病新药
- 批准号:
10698829 - 财政年份:2023
- 资助金额:
$ 35.74万 - 项目类别:
Antifungal discovery from previously uncultivated bacteria
从以前未培养的细菌中发现抗真菌药物
- 批准号:
10693593 - 财政年份:2023
- 资助金额:
$ 35.74万 - 项目类别:
Antibiotic tolerance as a stepping stone to tuberculosis drug-resistance
抗生素耐受性是结核病耐药性的垫脚石
- 批准号:
10592979 - 财政年份:2023
- 资助金额:
$ 35.74万 - 项目类别:
Developing triazolopyrimidines as novel anti-tubercular agents
开发三唑并嘧啶作为新型抗结核药物
- 批准号:
10672660 - 财政年份:2022
- 资助金额:
$ 35.74万 - 项目类别:
High content, high throughput, diversity screen for novel anti-tubercular agents targeting intracellular bacteria
针对细胞内细菌的新型抗结核药物的高含量、高通量、多样性筛选
- 批准号:
10526217 - 财政年份:2022
- 资助金额:
$ 35.74万 - 项目类别: